We are live on ! Find out more
TGI

TRV GP IV Portfolio holdings

AUM $267M
1-Year Est. Return 965.83%
This Fund
S&P 500
This Quarter Est. Return
+25.64%
1 Year Est. Return
+965.83%
3 Year Est. Return
+686.22%
5 Year Est. Return
+581.56%
10 Year Est. Return
–
AUM
$441M
AUM Growth
+$231M
Cap. Flow
+$223M
Cap. Flow %
50.6%
Top 10 Hldgs %
100%
Holding
5
New
1
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
TNGX icon
Tango Therapeutics
TNGX
+$232M

Top Sells

Rank Stock Value
1
DNTH icon
Dianthus Therapeutics
DNTH
+$9.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TNGX icon
1
Tango Therapeutics
TNGX
$4.43B
$250M 56.81%
+19,363,975
New +$232M
FULC icon
2
Fulcrum Therapeutics
FULC
$273M
$66.1M 15%
2,343,154
– –
DNTH icon
3
Dianthus Therapeutics
DNTH
$5.84B
$49.2M 11.16%
422,388
-78,125
-16% -$9.1M
RVMD icon
4
Revolution Medicines
RVMD
$39.9B
$39.1M 8.86%
1,419,900
– –
PLRX icon
5
Pliant Therapeutics
PLRX
$64.4M
$36M 8.17%
2,132,867
– –

Similar funds

OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
WAM
Weinberger Asset Management Los Angeles, California $267M AUM 19.83% 1-Year Est. Return
IP
Indigo Partners Phoenix, Arizona $267M AUM 9% 1-Year Est. Return
SIA
SGL Investment Advisors Missoula, Montana $266M AUM 18.29% 1-Year Est. Return
CFG
Cambridge Financial Group Columbus, Ohio $267M AUM 31.62% 1-Year Est. Return
EU
Emory University Atlanta, Georgia $267M AUM 48.26% 1-Year Est. Return
PC
Packer & Co Cottesloe, Australia $267M AUM
ALC
Alexander Labrunerie & Co Columbia, Missouri $267M AUM 21.24% 1-Year Est. Return

TRV GP IV's Q3 2021 Portfolio in Review

As of Q3 2021, TRV GP IV held 5 positions worth $441M, up 110% from $210M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

TRV GP IV deployed $223M of net new capital in Q3 2021, opening 1 new position. Its largest new stake was Tango Therapeutics: 19,363,975 shares worth $250M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Dianthus Therapeutics, an estimated $9.1M trimmed.

  • TRV GP IV's largest Q3 2021 buy was Tango Therapeutics: 19,363,975 shares worth $250M.
  • TRV GP IV's biggest Q3 2021 reduction was Dianthus Therapeutics, cutting an estimated $9.1M.
  • TRV GP IV's ten largest holdings make up 100% of its $441M portfolio in Q3 2021.
  • TRV GP IV opened 1 new position and closed 0 in Q3 2021.
  • TRV GP IV's portfolio value rose 110% quarter-over-quarter to $441M.

Based on TRV GP IV's 13F filing for Q3 2021, filed 5 Nov 2021.